Jubilant Pharmo

Which are the latest news on Jubilant Pharmo?

Why is Jubilant Pharmova Ltd falling/rising?

As of 05-Sep, Jubilant Pharmova Ltd's stock price is rising to 923.75, reflecting a 1.92% increase. This rise is driven by short-term performance improvements, positive sector comparison, and increased institutional investor confidence, despite longer-term underperformance.

As of 05-Sep, Jubilant Pharmova Ltd's stock price is rising, currently at 923.75, reflecting a change of 17.4 (1.92%) upwards. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 2.79% today and has shown consecutive gains over the last two days, with a total return of 2.43% during this period. Additionally, the stock reached an intraday high of Rs 928.35, indicating positive momentum.<BR><BR>In the context of recent performance, the stock has demonstrated a weekly gain of 4.73%, contrasting with a decline in the Sensex of 0.97%. However, it is important to note that the stock has underperformed over longer periods, with a year-to-date decline of 14.05% and a one-year drop of 13.24%. Despite these longer-term challenges, the current rise is supported by a favorable valuation, as the stock is trading at a discount compared to its peers' average historical valuations.<BR><BR>Moreover, high institutional holdings at 28.27% suggest confidence from larger investors, who have increased their stake by 0.75% over the previous quarter. This could indicate a belief in the stock's potential for recovery or growth, contributing to the current upward price movement. However, the stock's liquidity remains adequate for trading, which also supports its price stability.<BR><BR>In summary, the recent rise in Jubilant Pharmova Ltd's stock price is primarily driven by short-term performance improvements, positive sector comparison, and institutional investor confidence, despite the backdrop of longer-term underperformance and declining profits.

Who are in the management team of Jubilant Pharmo?

The management team of Jubilant Pharmo includes Chairman Shyam S Bhartia, Co-Chairman Hari S Bhartia, Managing Director Priyavrat Bhartia, Joint Managing Director Arjun Shanker Bhartia, and several other directors, bringing diverse expertise to the company. Key members also include CFO Arvind Chokhany and Company Secretary Naresh Kapoor.

The management team of Jubilant Pharmo includes the following key members:<BR><BR>1. **Shyam S Bhartia** - Chairman (Non-Executive)<BR>2. **Hari S Bhartia** - Co-Chairman & Non-Executive Director<BR>3. **Priyavrat Bhartia** - Managing Director<BR>4. **Arjun Shanker Bhartia** - Joint Managing Director<BR>5. **Arvind Chokhany** - Whole Time Director & CFO<BR>6. **R Kumar** - Whole Time Director<BR>7. **Naresh Kapoor** - Company Secretary & Compliance Officer<BR><BR>Additionally, the board includes several Non-Executive and Independent Directors:<BR>- **S Sridhar**<BR>- **Sudha Pillai**<BR>- **Ashok Misra**<BR>- **Vivek Mehra**<BR>- **Sushil Kumar Roongta**<BR>- **Arun Seth**<BR>- **Shirish Gundopant Belapure**<BR><BR>This diverse team brings a wealth of experience and expertise to the company.

What does Jubilant Pharmo do?

Jubilant Pharmova Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of ₹2,229 Cr and a net profit of ₹56 Cr for June 2026. The company has a market cap of ₹13,899 Cr and key metrics include a P/E ratio of 36.00 and a dividend yield of 0.57%.

Overview: <BR>Jubilant Pharmova Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>The company was initially incorporated as 'Vam Organic Chemicals Limited' in 1978. It underwent several name changes, becoming 'Jubilant Organosys Limited' in November 2001, 'Jubilant Life Sciences Limited' in October 2009, and finally 'Jubilant Pharmova Limited' in February 2021. The latest reported quarterly results indicate net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 2,229 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 56 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 13,899 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 36.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.57% <BR>Debt Equity: 0.33 <BR>Return on Equity: 6.14% <BR>Price to Book: 1.97<BR><BR>Contact Details: <BR>Address: Bhartiagram Gajraula, Amroha Uttar Pradesh: 244223 <BR>Tel: 91-5924-267200 <BR>Email: investors@jubl.com/support@jubl.com <BR>Website: http://www.jubilantpharmova.com

Who are the peers of the Jubilant Pharmo?

Jubilant Pharma's peers include Alivus Life, Alembic Pharma, Concord Biotech, Natco Pharma, Marksans Pharma, Akums Drugs, Viyash Scientifi, and Blue Jet Health. Most peers have excellent management and capital structures, while Jubilant Pharma has average management risk and capital structure, with a 1-year return of -13.44%.

Peers: The peers of Jubilant Pharmo are Alivus Life, Alembic Pharma, Concord Biotech, Natco Pharma, Marksans Pharma, Akums Drugs, Viyash Scientifi, and Blue Jet Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Alivus Life, Alembic Pharma, Concord Biotech, Natco Pharma, Marksans Pharma, and Blue Jet Health, while Average management risk is found at Jubilant Pharmo and Akums Drugs. Below Average management risk is noted for Viyash Scientifi. All peers exhibit Below Average growth except for Akums Drugs, which has Average growth, and Viyash Scientifi, which has Good growth. Excellent capital structure is seen at Alivus Life, Alembic Pharma, Concord Biotech, Natco Pharma, Marksans Pharma, Akums Drugs, and Blue Jet Health, while Average capital structure is found at Jubilant Pharmo and Below Average at Viyash Scientifi.<BR><BR>Return Snapshot: Marksans Pharma has the highest 1-year return at 91.38%, while Alembic Pharma has the lowest at -10.80%. Jubilant Pharmo's 1-year return of -13.44% is lower than both. Additionally, Natco Pharma and Viyash Scientifi have negative six-month returns.

How big is Jubilant Pharmo?

As of 31st August, Jubilant Pharmova Ltd has a market capitalization of 13,899.00 Cr, with net sales of 8,608.30 Cr and a net profit of 352.10 Cr reported in the latest four quarters.

As of 31st August, Jubilant Pharmova Ltd has a market capitalization of 13,899.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Jubilant Pharmova Ltd reported net sales of 8,608.30 Cr and a net profit of 352.10 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2026, with shareholder's funds amounting to 7,092.80 Cr and total assets of 15,265.60 Cr.

Should I buy, sell or hold Jubilant Pharmova Ltd?

When is the next results date for Jubilant Pharmova Ltd?

The next results date for Jubilant Pharmova Ltd is August 10, 2026.

The next results date for Jubilant Pharmova Ltd is scheduled for August 10, 2026.

Are Jubilant Pharmova Ltd latest results good or bad?

Jubilant Pharmova Ltd's latest results show strong revenue growth of 18.73% year-on-year, reaching ₹2,290 crores, and a significant sequential net profit recovery of 113.60%. However, concerns arise from a 22.27% year-on-year decline in net profit and a decrease in operating margin, indicating potential challenges in cost management.

Jubilant Pharmova Ltd's latest results present a mixed picture. On one hand, the company achieved a significant revenue growth of 18.73% year-on-year, reaching ₹2,290 crores in Q4 FY26, which is commendable and indicates strong sales momentum. Additionally, the net profit saw a remarkable sequential recovery, jumping 113.60% from the previous quarter to ₹119.40 crores.<BR><BR>However, there are notable concerns regarding profitability. The net profit declined by 22.27% year-on-year, and the operating margin (excluding other income) decreased to 14.93%, down 310 basis points from the same quarter last year. This margin compression raises questions about the company's ability to manage costs effectively, particularly as employee costs surged by nearly 30% year-on-year, significantly outpacing revenue growth.<BR><BR>In summary, while Jubilant Pharmova's revenue growth is impressive, the decline in profitability and rising costs suggest underlying challenges that the company needs to address. Investors should be cautious, as the strong revenue figures may not fully reflect the company's operational health.

Is Jubilant Pharmo technically bullish or bearish?

As of December 3, 2025, Jubilant Pharma's technical trend has shifted to a bearish outlook, supported by mildly bearish MACD and KST indicators, alongside mixed signals from moving averages and Bollinger Bands.

As of 3 December 2025, the technical trend for Jubilant Pharmo has changed from mildly bullish to sideways. The current technical stance is bearish, with key indicators supporting this view. The MACD is mildly bearish on both the weekly and monthly time frames, and the KST also shows a mildly bearish trend. The Bollinger Bands indicate a bearish sentiment on the weekly chart, while the moving averages on the daily chart are mildly bullish, suggesting mixed signals. Overall, the weakness in the weekly indicators and the sideways trend suggest a bearish outlook with limited strength.

How has been the historical performance of Jubilant Pharmo?

Jubilant Pharmo's historical performance shows fluctuating financial metrics, with net sales increasing from INR 6,130.16 crore in March 2022 to INR 7,234.50 crore in March 2025, despite a peak of INR 9,110.82 crore in March 2019. The company has rebounded in profitability, with profit after tax rising to INR 836.80 crore in March 2025 from a loss of INR 77.13 crore in March 2023.

Answer:<BR>The historical performance of Jubilant Pharmo shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Jubilant Pharmo's net sales have shown a steady increase from INR 6,130.16 crore in March 2022 to INR 7,234.50 crore in March 2025. However, this is a decline from the peak of INR 9,110.82 crore in March 2019. The total operating income followed a similar trend, reaching INR 7,234.50 crore in March 2025. The total expenditure, excluding depreciation, increased from INR 4,973.83 crore in March 2022 to INR 6,060.80 crore in March 2025. Operating profit (PBDIT) has fluctuated, peaking at INR 1,739.01 crore in March 2019 and dropping to INR 1,230.50 crore in March 2025. Profit before tax saw a significant recovery to INR 981.10 crore in March 2025, up from just INR 15.53 crore in March 2023. Profit after tax also rebounded to INR 836.80 crore in March 2025, compared to a loss of INR 77.13 crore in March 2023. The company's total assets increased from INR 9,829.60 crore in March 2022 to INR 12,499.00 crore in March 2025, while total liabilities rose from INR 9,829.60 crore to INR 12,499.00 crore in the same period. Cash flow from operating activities improved to INR 1,072.00 crore in March 2025, indicating a positive trend in cash generation. Overall, Jubilant Pharmo has demonstrated resilience with a recovery in profitability and growth in sales, despite facing challenges in previous years.

Is Jubilant Pharmo overvalued or undervalued?

As of November 3, 2025, Jubilant Pharma is fairly valued with a PE ratio of 37.37 and an EV to EBITDA of 14.49, positioned between peers like Sun Pharma and Cipla, despite facing challenges with an -8.16% return over the past year.

As of 3 November 2025, the valuation grade for Jubilant Pharmo has moved from attractive to fair. The company is currently fairly valued, with a PE ratio of 37.37, an EV to EBITDA of 14.49, and a PEG ratio of 1.35. In comparison to its peers, Sun Pharma has a PE ratio of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a more attractive PE of 22.44 and an EV to EBITDA of 5.66, indicating that Jubilant Pharmo is positioned in the middle range of its industry.<BR><BR>Despite recent stock performance showing a 4.09% gain over the past week compared to a -0.94% decline in the Sensex, the company's longer-term returns, particularly a -8.16% return over the past year, suggest some challenges ahead. Overall, the current valuation reflects a balance between growth expectations and market realities, placing Jubilant Pharmo in a fair valuation category amidst its peers.

Who are the top shareholders of the Jubilant Pharmo?

The top shareholders of Jubilant Pharma include Spb Trustee Company Pvt Ltd with 20.52%, 18 mutual fund schemes holding 3.66%, 151 foreign institutional investors at 17.22%, and East Bridge Capital Master Fund I Ltd as the largest public shareholder with 4.3%. Individual investors collectively own 17.75% of the shares.

The top shareholders of Jubilant Pharma include a mix of promoters and institutional investors. The majority shareholders are the promoters, with Spb Trustee Company Pvt Ltd holding the largest stake at 20.52%. <BR><BR>In terms of institutional holdings, 18 mutual fund schemes collectively hold 3.66% of the company, while 151 foreign institutional investors (FIIs) account for 17.22%. The highest public shareholder is East Bridge Capital Master Fund I Ltd, which holds 4.3%. Additionally, individual investors collectively own 17.75% of the shares.

Has Jubilant Pharmo declared dividend?

Yes, Jubilant Pharmova Ltd has declared a 500% dividend, amounting to ₹5 per share, with an ex-date of August 2, 2024. The company has shown strong total returns over longer periods, despite some short-term fluctuations.

Jubilant Pharmova Ltd has declared a 500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 500%<BR>- Amount per share: 5 per share<BR>- Ex-date: 02 Aug 2024<BR><BR>Dividend Yield: 0.44%.<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -5.83%, the dividend return was 0%, resulting in a total return of -5.83%.<BR><BR>For the 1 year period, the price return was 58.16%, the dividend return was 0.68%, leading to a total return of 58.84%.<BR><BR>Over the 2 years period, the price return was 235.09%, the dividend return was 2.44%, culminating in a total return of 237.53%.<BR><BR>In the 3 years period, the price return was 185.02%, the dividend return was 4.65%, which resulted in a total return of 189.67%.<BR><BR>During the 4 years period, the price return was 36.31%, the dividend return was 2.71%, giving a total return of 39.02%.<BR><BR>For the 5 years period, the price return was 98.97%, the dividend return was 2.94%, resulting in a total return of 101.91%.<BR><BR>Overall, Jubilant Pharmova Ltd has declared a significant dividend, and the total returns over various periods show a positive trend, particularly in the longer terms, indicating strong performance despite some short-term fluctuations.